Captor Therapeutics S.A. Asset Resilience Ratio
Captor Therapeutics S.A. asset resilience ratio. Captor Therapeutics S.A. (CTX) has an Asset Resilience Ratio of 71.95% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Captor Therapeutics S.A. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Captor Therapeutics S.A. (2022–2022)
Asset resilience ratio of Captor Therapeutics S.A. from 2022 to 2022. This chart shows how Captor Therapeutics S.A.'s Asset Resilience Ratio has changed over time. Read how much debt does Captor Therapeutics S.A. carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Captor Therapeutics S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Captor Therapeutics S.A. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł32.05 Million | 71.95% |
| Total Liquid Assets | zł32.05 Million | 71.95% |
Asset Resilience Insights
- Very High Liquidity: Captor Therapeutics S.A. maintains exceptional liquid asset reserves at 71.95% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Captor Therapeutics S.A. Industry Peers by Asset Resilience Ratio
Compare Captor Therapeutics S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Captor Therapeutics S.A. Asset Resilience Ratio by Year (2022–2022)
Captor Therapeutics S.A. asset resilience ratio by year from 2022 to 2022. The table below shows the annual Asset Resilience Ratio data for Captor Therapeutics S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 17.57% | zł19.85 Million ≈ $5.46 Million |
zł113.00 Million ≈ $31.10 Million |
-- |
About Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. … Read more